期刊文献+

雷珠单抗对房水中炎症相关细胞因子含量的影响 被引量:6

Effect of ranibizumab for intraocular inflammation-related cytokines levels in patients with neovascular glaucoma
下载PDF
导出
摘要 目的:比较新生血管性青光眼(neovascular glaucoma,NVG)与年龄相关性白内障患者房水中炎症相关细胞因子浓度,观察玻璃体腔内注射雷珠单抗前后房水中炎症相关细胞冈子表达变化。方法:纳入21例21眼NVG患者以及20例20眼年龄相关性白内障患者作为对照。NVG患者先予玻璃体腔内注射雷珠单抗,再行青光眼房水引流阀植入术。在玻璃体腔内注射雷珠单抗以及2~7d后行青光眼房水引流阀植入术术前抽取NVG患者房水,同时在白内障手术时抽取年龄相关性白内障患者房水。用Multiplex微珠免疫分析系统检测房水中细胞因子浓度。结果:NVG组患者玻璃体腔内注射雷珠单抗前房水中IL-1β,IL-6,IL-8,MCP-1以及VEGF浓度明显高于年龄相关性白内障患者,差异均有统计学意义(均P<0.001)。玻璃体腔内注射雷珠单抗后,NVG患者房水中IL-6,IL-8,MCP-1以及VEGF浓度较注射雷珠单抗前明显降低,差异有统计学意义(P<0.05)。NVG患者房水中检测的炎症相关细胞因子的浓度与患者年龄、术前眼压均无明显相关性。结论:NVG患者玻璃体腔内注射雷珠单抗前房水中与炎症相关的细胞因子表达明显上调。NVG患者行雷珠单抗治疗后,房水中与炎症相关的细胞因子明显下调。 ·AIM:To measure levels of various inflammation-related cytokines in the aqueous humor of patients with neovascular glaucoma ( NVG) and age-related cataract, and to evaluate changes in these cytokines before and after an intravitreal injection of ranibizumab. ·METHODS:This study investigated 21 eyes of 21 patients with NVG and 20 eyes of 20 control subjects with age-related cataract. The NVG eyes received an intravitreal injection of ranibizumab treatment before Ahmed glaucoma valve implantation. Aqueous humor was collected before intravitreal injection of ranibizumab and before Ahmed glaucoma valve implantation. Aqueous humor samples were collected from the cataract patients at the time of cataract surgery. The levels of inflammation-related cytokines in the aqueous humor were measured with a Multiplex bead immunoassay technique. ·RESULTS:The NVG eyes showed significantly elevated concentrations of interleukin ( IL ) - 1β, IL - 6, IL - 8, monocyte chemotactic protein-1 ( MCP-1 ) , and vascular endothelial growth factor (VEGF) (all P〈0. 001) when compared with the eyes of the cataract patients. Following the intravitreal injection of ranibizumab, the concentrations of IL-6, IL-8, MCP-1, and VEGF in the NVG eyes showed a dramatic and statistically significant decrease. The correlations between the levels of inflammation - related cytokines and age, intraocular pressure ( IOP) before operations in the NVG patients did not reach statistical significance. ·CONCLUSION:The inflammation-related cytokines were significantly elevated in NVG eyes. Intravitreal injection of&amp;nbsp;ranibizumab dramatically and significantly reduced the levels of some inflammation-related cytokines.
作者 许畅 毛晓春
出处 《国际眼科杂志》 CAS 2017年第4期643-647,共5页 International Eye Science
关键词 新生血管性青光眼 细胞因子 雷珠单抗 neovascular glaucoma cytokines ranibizumab
  • 相关文献

参考文献1

二级参考文献30

  • 1Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009, 24: 113-121.
  • 2Tzamalis A, Pham DT, Wirbelauer C. Diode laser cyclophotocoagulation versus cyclocryotherapy in the treatment of refractory glaucoma. Eur J Ophthalmol 2011, 21 : 589-596.
  • 3Fong AW, Lee GA, O'Rourke P, Thomas R. Management of neovascular glaucoma with transscleral cyclophoto- coagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser andintravitreal bevacizumab. Clin Experiment Ophthalmol 2011, 39: 318-323.
  • 4Netland PA. The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis). Trans Am Ophthalmol Soc 2009, 107: 325-342.
  • 5Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 2010, 88: 96-102.
  • 6Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009, 147:911-918.
  • 7Park UC, Park KH, Kim DM, Yu HG. Ahmed glaucoma valve implantation for neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy. J Glaucoma 2011, 20: 433-438.
  • 8Yasuda S, Kachi S, Kondo M, Ushida H, Uetani R, Terui T, et al. Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes. Invest Ophthalmol Vis Sci 2011, 52: 5737-5742.
  • 9Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004, 25:581-611.
  • 10Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009, 18: 632-637.

共引文献33

同被引文献73

引证文献6

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部